期刊文献+

吉西他滨维持治疗晚期非小细胞肺癌的疗效分析 被引量:2

下载PDF
导出
摘要 目的观察吉西他滨维持治疗晚期非小细胞肺癌的疗效及毒副反应。方法选取50例ⅢB~Ⅳ期非小细胞肺癌患者接受4周期的吉西他滨联合顺铂化疗,给予吉西他滨1250mg/m2,d1、8;顺铂25mg/m2,d1~5,21d为1个周期。将获得CR+PR+SD的38例患者随机分为试验组和对照组,试验组给予吉西他滨1000mg/m2,d1、8,21d为1个周期,行6周期化疗维持治疗;对照组给予最佳支持治疗。结果试验组和对照组的有效率分别为52.6%、26.3%,疾病进展时间分别为5.2、3.5个月,经比较差异均有统计学意义(P<0.01);总生存期分别为11.6、9.8个月,经比较差异无统计学意义(P>0.05);毒副反应一般轻微,最主要毒性反应是恶心、呕吐和骨髓抑制。结论吉西他滨维持治疗可以延长初治有效的非小细胞肺癌患者的疾病进展时间,毒副反应可耐受。
出处 《中国医药科学》 2012年第13期74-75,共2页 China Medicine And Pharmacy
  • 相关文献

参考文献6

  • 1Schiller JH, Harrington D, Belani CP, et al.Comparison of four chemotherapy regimens for advanced non-small cell lung cancer[J].N Engl J Med,2002,346 ( 2 ) : 92-98.
  • 2Pfister DG, Johnson DH, Azzoli CG, et al.America Society of Clinical Oncology treatment of unreseetable non-small cell lung cancer guideline : update 2003[J]. J Clin Oncol,2004,22 ( 2 ): 330.
  • 3I Stinchcombe TE, Socinki MA.Treatment paradigms for advanced stage non- small cell lung cancer in the era of multiple lines of therapy [J].J Thoracic Oncol,2009,4 ( 2 ): 243-250.
  • 4Therasse P, Arbuck S, Eisenhauer E, et al.New guidelines to evaluate the response to treatment in solid tumors[J].J Natl Cancer Inst,2000,92 ( 3 ): 205-216.
  • 5I Day RS.Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy[J].Cancer Res, 1986,g6 ( 8 ) : 3876-3885.
  • 6Brodowicz T, Krzakowski M, Zwitter M, et al.Cisplatin and gemcitabine firs- line chemotherapy followed by maintenance gemcitabine or best supportive Care in advanced non-small cell lung cancer: A phase Z trial[J].Lung Cancer,2006, 52 (2): 155.

同被引文献18

  • 1Brodowiez T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive.care in advanced non-small cell lung cancer: a phase Ill trial[ J J. Lung Cancer,2006,52 (2) :155-163.
  • 2Perol M, Chouaid C, Perol D, et al. Randomized, phase MI study of gemcitabine or erlotinib maintenance therapy versus observation ,with predefined second-line treatment, after cis- platin-gemcitabine induction chemotherapy in advanced non- small-cell lung cancer [ J ~. J Clin Oncol, 2012,30 ( 28 ) : 3516-3524.
  • 3Bepler G,Kusmartseva Irina,Sharma S,et al. RRM1 modula- ted in vitro and in vivo efficacy of Gemcitabine and platinum in non-small-cell lung cancer [ J J. J Clin Oncol, 2006,24 (29) :4731-4737.
  • 4Rosell R, Danenberg K, Alberola V, et al. Ribonucleotide re- ductase messenger RNA expression and survival in Gemcit- abine/Cisplatin treated advanced non-small-cell lung cancer patients[ JJ. Clin Cancer Res ,2004,10(4) : 1318-1325.
  • 5Patrick Therasse, Susan G, Arbuck, et al. New guidelines to evaluate the response to treatment in solid tumors[J]. J Natl Cancer Inst,2000,92(3 ) :205-216.
  • 6Simon G, Sharma A, Li X, et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in ad- vanced non-small-cell lung cancer ~ J 1. J Clin Oncol, 2007, 25 ( 19 ) :2741-2746.
  • 7朱军,张洁,周彩存.吉西他滨联合铂治疗晚期肺鳞癌与肺腺癌疗效分析[J].同济大学学报(医学版),2009,30(1):77-80. 被引量:12
  • 8张艳,苏欣,施毅.RRM1表达与吉西他滨治疗晚期NSCLC疗效关系:Meta分析[J].解放军医学杂志,2012,37(2):135-140. 被引量:6
  • 9郝利国,申宝忠,李任飞,杨坡,陈赤丹.中晚期非小细胞肺癌联合治疗进展[J].中国全科医学,2012,15(33):3812-3815. 被引量:75
  • 10朱川,刘良忠,熊德明,任必勇,李刚.吉西他滨联合洛铂治疗紫杉类耐药晚期肺鳞癌临床观察[J].中国基层医药,2014,21(12):1822-1824. 被引量:5

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部